{"nctId":"NCT02940860","briefTitle":"Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease","startDateStruct":{"date":"2016-11-29","type":"ACTUAL"},"conditions":["Iron Deficiency Anaemia","Iron Deficiency Anemia","Chronic Kidney Disease"],"count":1538,"armGroups":[{"label":"Iron isomaltoside/ferric derisomaltose","type":"EXPERIMENTAL","interventionNames":["Drug: Iron isomaltoside/ferric derisomaltose"]},{"label":"Iron sucrose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Iron sucrose"]}],"interventions":[{"name":"Iron isomaltoside/ferric derisomaltose","otherNames":["Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®"]},{"name":"Iron sucrose","otherNames":["Venofer®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria includes:\n\n1. Men and women, ≥ 18 years\n2. Hb ≤ 11 g/dL\n3. Chronic renal impairment, as defined by either (i) eGFR \\< 60 mL/min/1.73m2 at screening (as calculated by modification of diet in renal disease (MDRD)), or (ii) Estimated Glomerular Filtration Rate (eGFR) \\< 90 mL/min/1.73m2 at screening and kidney damage as indicated by abnormalities in urine composition per medical history and/or intermediate/high risk of cardio-vascular disease based on the Framingham model\n4. Screening s-ferritin ≤ 100 ng/mL, or ≤ 300 ng/mL if Transferrin Saturation (TSAT) ≤ 30 %\n5. Either no Erythropoiesis Stimulating Agent (ESAs) or ESAs as a stable dose 4 weeks before randomisation\n6. Willingness to participate and signing the informed consent form\n\nExclusion Criteria includes:\n\n1. Anaemia predominantly caused by factors other than IDA\n2. Hemochromatosis or other iron storage disorders\n3. Previous serious hypersensitivity reactions to any IV iron compounds\n4. Prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy\n5. Undergoing dialysis for treatment of CKD\n6. Planned surgical procedure within the trial period\n7. Decompensated liver cirrhosis or active hepatitis\n8. Alcohol or drug abuse within the past 6 month.\n9. Pregnant or nursing women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin (Hb) From Baseline to Week 8","description":"Efficacy\n\nEvaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).\n\nResponse was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":null},{"groupId":"OG001","value":"1.14","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions","description":"Safety\n\nFor this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness.\n\nThe potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).\n\nResults show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Cardiovascular Adverse Events (AEs)","description":"Safety\n\nResults show the composite cardiovascular AEs, that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8.\n\nThe reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).\n\nThe potential cardiovascular AEs included the following:\n\n* Death due to any cause\n* Non-fatal myocardial infarction\n* Non-fatal stroke\n* Unstable angina requiring hospitalisation\n* Congestive heart failure requiring hospitalisation or medical intervention\n* Arrhythmias\n* Hypertension\n* Hypotension\n\nResults show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Composite Cardiovascular Safety AE","description":"Safety\n\nTime to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint.\n\nTime to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8","description":"Safety\n\nResults show the number of participants who had s-phosphate \\<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8","description":"Efficacy\n\nResults show Hb responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 1 g/dL from baseline to the week in question was observed (from baseline to week 1, 2, 4, and 8).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430","spread":null},{"groupId":"OG001","value":"174","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"474","spread":null},{"groupId":"OG001","value":"226","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Change in Hb Concentration ≥1 g/dL","description":"Efficacy\n\nTime to change in Hb concentration ≥1 g/dL.\n\nSubjects who showed Hb concentration increase of ≥1 g/dL (from baseline to week 1, 2, 4, and 8).\n\nFor responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8","description":"Efficacy\n\nHb concentration of \\>12 g/dL at any time from week 1 to week 8.\n\nResults show the number of participants who achieved Hb concentration of \\>12 g/dL at any time from week 1 to week 8.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8","description":"Efficacy\n\nResults show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]}]},{"type":"SECONDARY","title":"S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8","description":"Efficacy\n\nProportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"873","spread":null},{"groupId":"OG001","value":"388","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hb Concentration From Baseline to Week 1, 2, and 4","description":"Efficacy\n\nChange in Hb concentration from baseline to week 1, 2, and 4.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.94"},{"groupId":"OG001","value":"0.21","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"1.16"},{"groupId":"OG001","value":"0.50","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"1.32"},{"groupId":"OG001","value":"0.90","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Change in S-ferritin From Baseline to Weeks 1, 2, 4, and 8","description":"Efficacy\n\nChanges in s-ferritin from baseline to weeks 1, 2, 4, and 8.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"492.4","spread":"309.7"},{"groupId":"OG001","value":"183.9","spread":"129.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381.2","spread":"283.8"},{"groupId":"OG001","value":"292.4","spread":"210.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258.4","spread":"214.5"},{"groupId":"OG001","value":"255.4","spread":"265.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191.3","spread":"196.1"},{"groupId":"OG001","value":"187.9","spread":"210.6"}]}]}]},{"type":"SECONDARY","title":"Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8","description":"Efficacy\n\nChanges in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.10","spread":"31.99"},{"groupId":"OG001","value":"4.31","spread":"23.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.84","spread":"29.79"},{"groupId":"OG001","value":"5.64","spread":"14.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.99","spread":"30.00"},{"groupId":"OG001","value":"5.59","spread":"12.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.10","spread":"30.17"},{"groupId":"OG001","value":"5.93","spread":"12.86"}]}]}]},{"type":"SECONDARY","title":"Change in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8","description":"Efficacy\n\nChanges in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":"99.7"},{"groupId":"OG001","value":"11.1","spread":"71.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"90.6"},{"groupId":"OG001","value":"12.4","spread":"44.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"91.2"},{"groupId":"OG001","value":"10.2","spread":"38.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"91.3"},{"groupId":"OG001","value":"12.4","spread":"41.9"}]}]}]},{"type":"SECONDARY","title":"Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8","description":"Efficacy\n\nChange in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale.\n\nThe Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52.\n\nA score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated.\n\nTotal score was calculated as shown below:\n\nTotal score= Sum of individual scores x 13 / Number of items answered","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","spread":"8.85"},{"groupId":"OG001","value":"5.01","spread":"7.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.29","spread":"9.84"},{"groupId":"OG001","value":"7.63","spread":"9.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.13","spread":"11.09"},{"groupId":"OG001","value":"9.07","spread":"11.40"}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"410","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Care Resource Use Questionnaire","description":"Pharmacoeconomics\n\nResources used by the health care staff (per administration), measured by the health care resource use questionnaire.\n\nThe questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":null},{"groupId":"OG001","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":null},{"groupId":"OG001","value":"2.33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83,"n":1019},"commonTop":["Urinary tract infection","Hyperkalaemia","Hypertension"]}}}